Purpose: To identify studies that described use of any patient-reported outcome scale for hearing loss or tinnitus among children, adolescents and young adults (AYAs) with cancer or hematopoietic stem cell transplantation (HSCT) recipients.
any patient-reported scale of hearing loss or tinnitus among children and AYAs with cancer or HSCT recipients. Only English language publications were included. Two reviewers identified studies and abstracted data.
Results: There were 953 studies screened; six met eligibility criteria. All studies administered hearing patient-reported outcomes only once, after therapy completion.
None of the studies described the psychometric properties of the hearing-specific component. Three instruments (among six studies) were used: Health Utilities Index, Hearing Measurement Scales and the Tinnitus Questionnaire for Auditory Brainstem Implant. All had limitations precluding routine use for hearing assessment in this population.
Conclusions:
We identified few studies that included hearing patient-reported measures for children and AYA cancer and HSCT patients. None are ideal to take forward into future studies. Future work should focus on the creation of a new psychometrically sound instrument for hearing outcomes in this population.
INTRODUCTION
Some children and adolescents who receive chemotherapy or who undergo hematopoietic stem cell transplantation (HSCT) are at risk of hearing loss and tinnitus. (Sung et al., 2003) Hearing loss is associated with platinum chemotherapy and cranial irradiation in addition to ototoxic supportive care medications such as loop diuretics and aminoglycosides as examples. Hearing loss is detectable in 20-60% of childhood cancer survivors who received platinum-based treatment. (Hudson et al., 2013) It has educational, vocational and social consequences that may vary by age of onset. (Bertolini et al., 2004; Brock et al., 2012; Langer, am Zehnhoff-Dinnesen, Radtke, Meitert, & Zolk, 2013; Travis et al., 2014) Tinnitus is another important hearing outcome which is common following platinum chemotherapy. It is important because it interferes greatly with sleep, daily function and quality of life. (Sprauten et al., 2012) In addition to objective measures of hearing such as conventional and high frequency audiometry and oto-acoustic emission evaluation, patient-reported measures of hearing are important. Patient-reported outcomes (PROs) evaluate symptoms, signs, or functioning from the patient perspective. They are important as an adjunct to objective measures to evaluate the impact of the symptom from the patient's perspective, to document how hearing loss impacts on usual patient activities and to understand how symptoms affect quality of life. (Basch, 2014) disease on persons was classified as impairment (abnormality of psychology, physiology, structure or function), disability (restricted ability to perform an activity) and handicap (limitation or prevention of a role due to impairment or disability). These dimensions may be measured through PROs, proxy-reported or objectively measured.
For example, hearing loss may be objectively measured using audiometry, proxyreported by parents or self-reported by patients. Similarly listening disability may be measured through proxy-report or patient report, as may be orientation handicaps. This review is focused on PROs related to hearing and included impairment, disability and handicap.
The incorporation of PROs for hearing outcomes is important in clinical trials
designed to test oto-protectants or to evaluate interventions with potentially different effects on hearing. However, it is not known whether reliable and valid PROs of hearing outcomes are available in pediatric cancer. It is particularly relevant to measure hearing PROs in adolescents and young adults (AYAs) in addition to children since this population is at risk for germ cell tumor and osteosarcoma, which are commonly treated with platinum agents. (Birch et al., 2002; Bleyer & Barr, 2009 ) Further, there is a lack of available instrumentation to measure PROs in general across the AYA age spectrum since most instruments have been validated in children or adults separately but rarely across the AYA continuum. (Taylor et al., 2015) The objective of this systematic review was to identify studies that described use of any patient-reported scale of hearing loss or tinnitus among children and AYA cancer patients or HSCT recipients in order to guide instrument selection for future clinical trials in this population. Two reviewers (DS and LS) abstracted all data in duplicate and any discrepancies were resolved by consensus. Study level variables of interest were year of publication, dates in which patients were diagnosed, country of study population, language of hearing instrument administration, name of instrument used to measure hearing loss or tinnitus, recall period for hearing symptoms, how measure was completed, age of participants, study eligibility, and number of participants. We also abstracted who completed the PRO measure in addition to the participant, whether administration was on or off therapy, the number of hearing assessments performed and whether any evaluation of psychometric properties, namely reliability, validity or responsiveness, was reported in the manuscript or referred to in another publication.
In terms of the actual measures, we recorded the number of questions related to 8 hearing symptoms and the number of hearing domains captured.
Assessment of Study Quality and Statistical Methods
Two reviewers assessed study quality and any discrepancies were resolved by consensus. Study quality was assessed using a modified version of an instrument previously developed to describe quality in studies of prognosis. (Hayden, Cote, & Bombardier, 2006) This quality assessment instrument examines four potential sources of bias: study participation, study attrition, confounding variables and measurement of outcomes. Relevant to this systematic review, we abstracted data on bias related to study participation and measurement of outcomes; they were rated as having low, medium or high risk of bias for each study. (Hayden et al., 2006) The systematic review analysis was descriptive.
RESULTS
The flow of study identification and selection is illustrated as Figure 1 . There were 953 studies identified by the search strategy, of which 73 were retrieved for full evaluation. Six met eligibility criteria and were included in the systematic review. (Barr et al., 2000; Einar-Jon et al., 2011; Einarsson et al., 2011; Fu et al., 2006; Kennedy et al., 2014; Soussi & Otto, 1994) Agreement of study inclusion between the two reviewers was kappa=1.00.
Characteristics of these studies are illustrated in Table 1 . None of the studies were at low risk of bias for study participation or measurement of outcomes. Three of the studies used the Health Utilities Index, (Barr et al., 2000; Fu et al., 2006; Kennedy et 9 al., 2014) two used the Hearing Measurement Scale, (Einar-Jon et al., 2011; Einarsson et al., 2011) and one used the Tinnitus Questionnaire for Auditory Brainstem Implant (ABI). (Soussi & Otto, 1994) Language of administration included English, Spanish, Swedish and Icelandic. All the studies had a small number of participants who were known to self-report hearing PROs with the largest study including 51 self-report participants. All studies administered the questionnaire to participants who had completed therapy and all studies only administered the questionnaire once.
None of the studies specifically stated that the hearing reported aspect of the questionnaire (if a multi-domain instrument) or the questionnaire itself (if instrument focused on hearing) was previously shown to be reliable, valid or responsive in children or AYA patients. None were explicitly designed to evaluate psychometric properties related to hearing. Table 2 summarizes the three instruments used in the studies. The number of hearing questions ranged from 5 to 44. Two of the instruments (Hearing Measurement Scale and Health Utilities Index) return hearing-specific summary scores whereas the Tinnitus Questionnaire for ABI does not return an overall score. With respect to face validity and from a hearing-specific perspective, none of the questionnaires appeared ideal based upon the number of questions, relevance and wording for children and AYA cancer or HSCT patients. For example, difficulty hearing conversation at work would have little relevance to children.
DISCUSSION
In this systematic review, we identified only six studies which explicitly measured hearing-specific PROs in children and AYAs with cancer or HSCT recipients. More importantly, none of the studies described that the hearing-specific instrument was psychometrically evaluated within this population such that it could be used confidently in future clinical trials. (Reeve et al., 2013) The studies all included a small number of participants and were all at moderate or high risk of bias. Consequently, we have demonstrated a gap in the literature related to PROs of hearing outcomes for children and AYA patients. 
